黑料网

Abstract

Neurologic adverse events (NAEs) associated with immune checkpoint inhibitors (ICIs) have emerged as significant complications in cancer immunotherapy. While ICIs have revolutionized the treatment of various malignancies, their role in eliciting immune-related adverse events, particularly affecting the nervous system, presents challenges in clinical management. NAEs can manifest as peripheral neuropathies, encephalitis, myasthenia gravis, and other neurologic disorders, often occurring weeks to months after treatment initiation. Early recognition and prompt intervention are crucial for mitigating potential long-term morbidity. This review examines the clinical presentation, incidence, risk factors, diagnostic evaluation, and management strategies for neurologic adverse events linked to ICIs. Emphasizing a multidisciplinary approach, we highlight the importance of tailored treatment plans that balance the therapeutic benefits of ICIs with the risks of neurologic complications. As research progresses, a deeper understanding of these events will enhance patient care and outcomes in the context of cancer immunotherapy [1].